Bazhanov V S, Shorin V A
Antibiotiki. 1981 Sep;26(9):694-6.
The antitumor activity of bleomycetin or bleomycin A5 was studied with respect to sarcoma 180, Garding-Passey melanoma, cervical carcinoma CC-5 and lymphosarcoma L10-1. Bleomycetin showed a high selective effect on the solid form of sarcoma 180. Its activity against Garding-Passeys melanoma and cervical carcinoma CC-5 was lower. Lymphosarcoma L10-1 was most resistant to bleomycetin. The intravenous route of bleomycin administration had no advantages over subcutaneous administration of the antibiotic.
研究了博来霉素或博来霉素A5对肉瘤180、加丁-帕西黑色素瘤、宫颈癌CC-5和淋巴肉瘤L10-1的抗肿瘤活性。博来霉素对肉瘤180的实体瘤形式表现出高选择性作用。其对加丁-帕西黑色素瘤和宫颈癌CC-5的活性较低。淋巴肉瘤L10-1对博来霉素最耐药。博来霉素静脉给药途径相对于皮下注射该抗生素并无优势。